glp-1 receptor agonist and dpp-4 inhibitor combination not recommended combining with guideline GLP-1 receptor agonists or DPP-4 inhibitors: How to guide the clinician? DPP-4 inhibitors for type 2

Professional society guidelines now recommend GLP therapy for cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease or multiple cardiac risk factors

Each type of denial requires a different appeal strategy

Doyle ME, and Egan JM

Acknowledgments The authors would like to acknowledge the Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Al-Koura, Lebanon

Ultra-processed diets cause excess calorie intake and weight gain: An inpatient randomized controlled trial of ad libitum food intake

When GLP-1RAs act on the gastrointestinal tract, they could extend the gastric emptying time